AbbVie abandons late-stage lung cancer asset Rova-TAcquisitions, Antibodies, Cancer, Clinical Trials, Data Monitoring Committee (DMC), Delta-like protein 3 (DLL3), Product Pipelines, R&DAbbVie Inc. will cease to develop the experimental drug Rova-T after failing to show survival benefit in a late-stage trial for a type of lung cancer. Read more August 29, 2019/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2019-08-29 09:05:292019-08-29 13:32:20AbbVie abandons late-stage lung cancer asset Rova-T
